Expression of the Mig (CXCL9) gene in murine lung carcinoma cells generated angiogenesis-independent antitumor effects

Oncology Reports

Volumn 10, Issue 4, 2003, Pages 909-913

  Wang, Yan Qing ^a,b   Wada, Akihiko ^a,c   Ugai, Shin Ichi ^a,c   Tagawa, Masatoshi ^a  

^a CHIBA CANCER CENTER   (Japan)

^b FUDAN UNIVERSITY   (China)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Lung cancer; Mig; RT PCR

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE RECEPTOR; CXC CHEMOKINE RECEPTOR 3; CXCL9 PROTEIN, HUMAN; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LEWIS CARCINOMA; LUNG TUMOR; METABOLISM; MOUSE; NATURAL KILLER CELL; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; T LYMPHOCYTE; VASCULARIZATION;

ANIMALS; ANTIGENS, CD; CARCINOMA, LEWIS LUNG; CHEMOKINES, CXC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; T-LYMPHOCYTES; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1542682327     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.4.909     Document Type: Article

References (19)

1. Tagawa M: Cytokine therapy for cancer. Curr Pharm Des 6: 681-699, 2000.
2. Tahara H and Lotze MT: Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 2: 96-106, 1995.
3. Tasaki K, Yoshida Y, Maeda T, Miyauchi M, Kawamura K, Takenaga K, Yamamoto H, Kouzu T, Asano T, Ochiai T, Sakiyama S and Tagawa M: Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther 7: 247-254, 2000. (Pubitemid 30194559)
4. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, Iannettoni MD and Strieter RM: The CXC chemokine, monokine induced by interferon-y, inhibits nonsmall cell lung carcinoma tumor growth and metastasis. Hum Gene Ther 11: 247-261, 2000. (Pubitemid 30080383)
5. Li S, Zhang X and Xia X: Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 94: 762-768, 2002. (Pubitemid 34567961)
6. Huang S, Xie K, Bucana CD, Ullrich SE and Bar-Eli M: Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2: 1969-1979, 1996. (Pubitemid 27006629)
7. Dorsey R, Kundu N, Yang Q, Tannenbaum CS, Sun H, Hamilton TA and Fulton AM: Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-γ. Cancer Res 62: 2606-2610, 2002. (Pubitemid 34462741)
8. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P and Farber JM: Human Mig chemokine: biochemical and functional characterization. J Exp Med 182: 1301-1314, 1995.
9. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ and Oppenheim JJ: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med 177: 1809-1814, 1993. (Pubitemid 23146150)
10. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61: 246-257, 1997.
11. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M and Moser B: Chemokine receptor specific for IP 10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963-969, 1996.
12. Takasu M, Tada J, O-Wang J, Tagawa M and Takenaga K: Resistance to apoptosis induced by microenvironmental stresses is correlated with metastatic potential in Lewis lung carcinoma, Clin Exp Metastasis 17: 409-416, 1999. (Pubitemid 30019998)
13. Farber JM: A macrophage mRNA selectively induced by γ-interferon encodes a member of the platelet factor 4 family of cytokines. Proc Natl Acad Sei USA 87: 5238-5242, 1990.
14. Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T and Tagawa M: T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells. Int J Mol Med 9: 281-285, 2002.
15. Palmer K, Hitt M, Emtage PC, Gyorffy S and Gauldie J: Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 8: 282-290, 2001. (Pubitemid 32237061)
16. Ruehlmann JM, Xiang R, Niethammer AG, Ba Y, Pertl U, Dolman CS, Gillies SD and Reisfeld RA: MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and issemination of murine colon carcinoma. Cancer Res 61: 8498-8503, 2001. (Pubitemid 33131131)
17. Osaki T, Péron JM, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT and Tahara H: IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J Immunol 160: 1742-1749, 1998. (Pubitemid 28106460)
18. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM and Hamilton TA: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161: 927-932, 1998. (Pubitemid 28323558)
19. Li S, Xia X, Zhang X and Suen J: Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther 9: 390-397, 2002. (Pubitemid 34414037)